Yearly Median Technologies liquidity contract statement contracted with AUREL BGC Company

Investors

Yearly Median Technologies liquidity contract statement contracted with AUREL BGC Company

4 January 2017, Sophia Antipolis, France

Under the liquidity contract entrusted by Median Technologies to AUREL BGC, the following resources were listed in the liquidity account as at December 31, 2016:

€ 123,128.68
13,807 shares

For information, as at June 30, 2016, the following resources were listed in the liquidity account:

€ 72,165.89
18,833 shares

About Median Technologies

alternext_almdt_modified Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017. Median Technologies has been awarded the 2017 Tech 40 Label and has joined the EnterNext Tech 40 Index. Median is a member of the Bpifrance Excellence Network. More information: www.mediantechnologies.com

peapme